ArticleScientific reports2026
Synthesis and characterization of a new N4-Schiff base its zinc halide/pseudohalide complexes with thermal, antimicrobial, antioxidant, anticancer, DNA cleavage and wound healing properties.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel Schiff base ligand, N¹,N²-bis(2-(((1E,2E)-3-(2-methoxyphenyl)allylidene)amino)ethyl)ethane-1,2-diamine (L), was synthesized from triethylenetetramine and o-methoxycinnamaldehyde, and its six new zinc halide/pseudohalide complexes were prepared and characterized using molar conductance measurements, melting point analysis and spectroscopic techniques. Thermogravimetric and differential thermal analyses (TG/DTG/DTA) coupled with the Coats-Redfern method provided key thermo-kinetic activation parameters (A*, E*, ΔH*, ΔG*, ΔS*) for the synthesized complexes. In vitro, zinc(II) complexes with Cl⁻, N₃⁻, and NO₃⁻ exhibited superior antimicrobial activity against Gram-positive (B. subtilis and S. aureus), Gram-negative (E. coli and P. aeruginosa) bacteria, and fungi (C. albicans and A. oryzae) compared to the free ligand. In DPPH and FRAP assays, zinc complexes, especially ZnL(N₃)₂ and ZnLI₂, exhibited superior antioxidant activity compared to the SB-ligand. In the MTT assay, ZnLI₂ and ZnL(NCS)₂ showed the highest anticancer activity against MCF-7 and PC3 cells, respectively. ZnLBr₂, ZnL(NCS)₂, ZnL(NO₃)₂, and ZnL(N₃)₂ completely cleaved E. coli DNA via a non-oxidative hydrolytic mechanism. Finally, the wound-healing potential of the SB-ligand and its ZnLI
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.